Back to top

LifeSci Capital Remains a Buy on Prime Medicine, Inc. (PRME)

LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $6.00. According to Ti...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Prime Medicine, Inc. (PRME)